Full Title
A Phase Ib/II Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-pretreated Metastatic Clear Cell Renal Cell CarcinomaPurpose
Researchers want to find the best doses of abemaciclib and cabozantinib to use in people with advanced kidney cancer. The people in this study have clear cell renal cell carcinoma that metastasized (spread); they previously received other kidney cancer therapies. In addition, their cancer keeps growing even after 2 or 3 prior treatments, including checkpoint inhibitor immunotherapy.
Abemaciclib targets and blocks CKD4/6, a protein that plays a role in cancer growth and survival. Cabozantinib blocks blood vessel growth around cancers, as well as proteins that promote cancer growth in different ways. Together these medications may help slow or stop kidney cancer growth. Both drugs are taken orally (by mouth).
Contact
For more information or to see if you can join this study, please call Dr. Martin Voss’ office at 646-888-4721.